Minocycline HCl

別名：CL 59806

製品コード：S4226 純度：99.94%

Minocycline HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.

CAS No. 13614-98-7

サイズ	価格(税別)	在庫状況
50mg	JPY 22000	国内在庫あり
200mg	JPY 41800	国内在庫あり
1g	JPY 70500	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（34）

製品安全説明書

現在のバッチを見る：純度： 99.94%

99.94

Minocycline HCl関連製品

関連化合物ライブラリー	Anti-infection Compound Library Antibiotics compound Library Antiviral Compound Library Anti-parasitic Compound Library Gut Microbial Metabolite Library	もっと見る

Antibiotics阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
Jurkat cells	Cell viability assay	10-200 µM	24 h	reduces cell viability and induces DNA fragmentation and dissipation of the mitochondrial membrane potential in Jurkat cells but is harmless to human peripheral blood lymphocyte cells (hPBLCs)	29625165
hPBLCs	Cell viability assay	10-200 µM	24 h	reduces cell viability and induces DNA fragmentation and dissipation of the mitochondrial membrane potential in Jurkat cells but is harmless to human peripheral blood lymphocyte cells (hPBLCs)	29625165
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明	Minocycline HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.

In Vitro
In vitro	Minocycline is a second-generation tetracycline used in humans, which effectively crosses the blood−brain barrier. It inhibits the activity of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK). After experimental ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase (iNOS) upregulation, and decreases infarct size. Minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release. Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria. ^[2]
細胞実験	細胞株	OVCAR-3, SKOV-3 and A2780 cells
	濃度	IC50 values of 62.0, 56.1 and 59.5 μM, respectively
	反応時間	72 h
	実験の流れ	Cells were treated with various concentrations of drug for 72 h.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	IL-6Rα / gp130 p-STAT3 / STAT3 / Mcl-1 / p-ERK / ERK		23593315
	Immunofluorescence	p-STAT3 STAT3		23593315
	Growth inhibition assay	Cell viability		27555377

In Vivo
In Vivo	Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). ^[1] Minocycline is remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, and Huntington's and Parkinson's disease. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging. ^[3]

In Vivo

Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). ^[1]

Minocycline is remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, and Huntington's and Parkinson's disease. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging. ^[3]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05605366	Not yet recruiting	Sickle Cell Disease\|Cognitive Impairment\|Cognitive Decline\|Cognitive Change\|Cognitive Dysfunction\|Cognitive Deficit\|Neuroinflammatory Response	University of Cincinnati	June 1 2024	Phase 1
NCT05861258	Recruiting	Mycobacterium Avium Complex Pulmonary Disease	Radboud University Medical Center	May 8 2023	Phase 2
NCT05630534	Not yet recruiting	Intracerebral Hemorrhage	Second Affiliated Hospital School of Medicine Zhejiang University\|The Fourth Affiliated Hospital of Zhejiang University School of Medicine\|The Second Affiliated Hospital of Jiaxing University	January 1 2023	Phase 1
NCT05680389	Recruiting	Cerebral Amyloid Angiopathy	Leiden University Medical Center	December 2 2020	Phase 1\|Phase 2

参考
[1] Brogden RN, et al. Drugs, 1975, 9(4), 251-291. [2] Zhu S, et al. Nature, 2002, 417(6884), 74-78. [3] Wang X, et al. Proc Natl Acad Sci U S A, 2003, 100(18), 10483-10487. [4] Pourgholami MH, et al. Gynecol Oncol. 2012 May;125(2):433-40. + 展開

参考

[4] Pourgholami MH, et al. Gynecol Oncol. 2012 May;125(2):433-40.

+ 展開

化学情報

分子量	493.94	化学式	C₂₃H₂₇N₃O₇.HCl
CAS No.	13614-98-7	SDF	Download Minocycline HCl SDFをダウンロードする
Smiles	CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

Water : 6 mg/mL

DMSO : Insoluble ( 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):